Nahdi Medical Company
Nahdi Medical Company (4164.SR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
4164.sr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Nahdi Medical Company (4164.SR) measures how much investors pay for each dollar of the company's trailing earnings. 4164.SR's current PE ratio of 15.31x is calculated by dividing its stock price of $95.40 by its TTM earnings per share of $6.23. −25.3% discount vs 5Y avg 20.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 9 fiscal years · Front-end computedMinQ1 · 25%24.0x
MedianQ3 · 75%31.9x
Max
At 15.31x, 4164.SR's current P/E is lower than in 11% of its annual fiscal year readings over the past 9 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nahdi Medical CompanyYou 4164.SR | $12.4B | 15.31x | -25.2% | $6.23 |
 Mouwasat Medical Services Company 4002.SR | $13.3B | 16.22x | -20.8% | $4.11 |
 Dallah Healthcare Company 4004.SR | $11.6B | 23.59x | +15.2% | $5.32 |
 National Medical Care Company 4005.SR | $4.8B | 20.01x | -2.2% | $7.13 |
 Al Hammadi Holding Company 4007.SR | $4.5B | 18.53x | -9.5% | $1.51 |
 Jamjoom Pharmaceuticals Factory Company 4015.SR | $11.2B | 21.56x | +5.3% | $6.60 |
 Middle East Pharmaceutical Industries Company 4016.SR | $2.2B | 22.93x | +12.0% | $2.77 |
Industry Average 6 peers with valid PE | — | 20.47x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 14.87x | $6.39 | -20.2% | |
2024-12-31 FY2024 | 18.63x | $6.31 | -6.6% | |
2023-12-31 FY2023 | 19.95x | $6.87 | -20.6% | |
2022-12-31 FY2022 | 25.13x | $6.83 | +4.7% | |
2021-12-31 FY2021 | 24.00x | $6.25 | +4.5% | |
2020-12-31 FY2020 | 22.97x | $6.53 | -18.5% | |
2019-12-31 FY2019 | 28.18x | $5.32 | -11.8% | |
2018-12-31 FY2018 | 31.93x | $4.70 | +18.1% | |
2017-12-31 FY2017 | 27.04x | $5.55 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nahdi Medical Company (4164.SR) measures how much investors pay for each dollar of the company's trailing earnings. 4164.SR's current PE ratio of 15.31x is calculated by dividing its stock price of $95.40 by its TTM earnings per share of $6.23.
Frequently asked questions
4164.SR pe ratio · 6 questions4164.SR's current PE ratio is 15.31x as of 2026-06-15, based on a stock price of $95.40 and TTM EPS of $6.23. Data sourced from Financial Modeling Prep via 4164.SR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nahdi Medical Company SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15